# STI-6129

Source: https://onco.cc/drugs/sti-6129/  
OnCo record `sti-6129` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

STI-6129 is an experimental antibody-drug conjugate from Zhejiang ACEA Pharmaceutical in phase 2 trials for multiple myeloma, aimed at CD38.

## Summary

STI-6129 is an antibody-drug conjugate developed by Zhejiang ACEA Pharmaceutical. Its target is CD38 (the sponsor names CD38). The sponsor states: Anti-CD38 human antibody covalently bound to a duostatin tubulin inhibitor payload. ClinicalTrials.gov describes the intervention as: Anti-CD38 A2 human antibody drug conjugate (ADC) containing an antibody covalently bound to a duostatin tubulin inhibitor. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in multiple myeloma. The largest, NCT05565807, plans to enrol 84 participants with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: Anti-CD38 human antibody covalently bound to a duostatin tubulin inhibitor payload.

## Sources

- ClinicalTrials.gov: trials of STI-6129: https://clinicaltrials.gov/search?intr=STI-6129

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- targets: [CD38](https://onco.cc/targets/cd38/)
- companies: [Sorrento Therapeutics](https://onco.cc/companies/sorrento-therapeutics/)
- trials: [Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma](https://onco.cc/trials/nct05565807/)

---
JSON: https://onco.cc/api/v1/entities/sti-6129.json